Clinical characteristics and outcomes of oropharyngeal carcinoma related to high-risk non–human papillomavirus16 viral subtypes
Indu Varier MD
Department of Otolaryngology – Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA
Search for more papers by this authorBrieze R. Keeley MD
Department of Otolaryngology – Head and Neck Surgery, Icahn School of Medicine, NY, USA
Search for more papers by this authorRosemarie Krupar MD
Department of Otolaryngology – Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA
Search for more papers by this authorAlexis Patsias MD
Department of Otolaryngology – Head and Neck Surgery, Icahn School of Medicine, NY, USA
Department of Otolaryngology – Head and Neck Surgery, University Oklahoma Health Sciences Center, OK, USA
Search for more papers by this authorJoanna Dong BS
Department of Otolaryngology – Head and Neck Surgery, Icahn School of Medicine, NY, USA
Search for more papers by this authorNikita Gupta MD
Department of Otolaryngology – Head and Neck Surgery, Icahn School of Medicine, NY, USA
Search for more papers by this authorArjun K. Parasher MD
Department of Otolaryngology – Head and Neck Surgery, Icahn School of Medicine, NY, USA
Search for more papers by this authorEric M. Genden MD, MHCA
Department of Otolaryngology – Head and Neck Surgery, Icahn School of Medicine, NY, USA
Search for more papers by this authorBrett A. Miles MD
Department of Otolaryngology – Head and Neck Surgery, Icahn School of Medicine, NY, USA
Search for more papers by this authorMarita Teng MD
Department of Otolaryngology – Head and Neck Surgery, Icahn School of Medicine, NY, USA
Search for more papers by this authorRichard L. Bakst MD
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, NY, USA
Search for more papers by this authorVishal Gupta MD
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, NY, USA
Search for more papers by this authorKrzysztof J. Misiukiewicz MD
Department of Medical Oncology, Icahn School of Medicine at Mount Sinai, NY, USA
Search for more papers by this authorElizabeth Y. Chiao MD, MPH
Department of Internal Medicine and Health Services Research, Baylor College of Medicine, Houston, TX, USA
Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center, Houston, TX, USA
Search for more papers by this authorMichael E. Scheurer PhD, MPH
Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine, Houston, TX, USA
Search for more papers by this authorSimon Laban MD
Head and Neck Cancer Center Ulm, Department of Oto-Rhino-Laryngology and Head and Neck Surgery, University Medical Center Ulm, Ulm, Baden-Württemberg, Germany
Search for more papers by this authorDavid Zhang MD, MPH, PhD
Department of Pathology, Icahn school of Medicine at Mount Sinai, NY, USA
Search for more papers by this authorFei Ye MD
Department of Pathology, Icahn school of Medicine at Mount Sinai, NY, USA
Search for more papers by this authorMiao Cui MD
Department of Pathology, Icahn school of Medicine at Mount Sinai, NY, USA
Search for more papers by this authorElizabeth G. Demicco MD
Department of Pathology, Icahn school of Medicine at Mount Sinai, NY, USA
Search for more papers by this authorMarshall R. Posner MD
Department of Medical Oncology, Icahn School of Medicine at Mount Sinai, NY, USA
Search for more papers by this authorCorresponding Author
Andrew G. Sikora MD, PhD
Department of Otolaryngology – Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA
Corresponding author: A. G. Sikora, Bobby R. Alford Department of Otolaryngology–Head and Neck Surgery, One Baylor Plaza, NA-102, Houston, TX 77030. E-mail: [email protected]Search for more papers by this authorIndu Varier MD
Department of Otolaryngology – Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA
Search for more papers by this authorBrieze R. Keeley MD
Department of Otolaryngology – Head and Neck Surgery, Icahn School of Medicine, NY, USA
Search for more papers by this authorRosemarie Krupar MD
Department of Otolaryngology – Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA
Search for more papers by this authorAlexis Patsias MD
Department of Otolaryngology – Head and Neck Surgery, Icahn School of Medicine, NY, USA
Department of Otolaryngology – Head and Neck Surgery, University Oklahoma Health Sciences Center, OK, USA
Search for more papers by this authorJoanna Dong BS
Department of Otolaryngology – Head and Neck Surgery, Icahn School of Medicine, NY, USA
Search for more papers by this authorNikita Gupta MD
Department of Otolaryngology – Head and Neck Surgery, Icahn School of Medicine, NY, USA
Search for more papers by this authorArjun K. Parasher MD
Department of Otolaryngology – Head and Neck Surgery, Icahn School of Medicine, NY, USA
Search for more papers by this authorEric M. Genden MD, MHCA
Department of Otolaryngology – Head and Neck Surgery, Icahn School of Medicine, NY, USA
Search for more papers by this authorBrett A. Miles MD
Department of Otolaryngology – Head and Neck Surgery, Icahn School of Medicine, NY, USA
Search for more papers by this authorMarita Teng MD
Department of Otolaryngology – Head and Neck Surgery, Icahn School of Medicine, NY, USA
Search for more papers by this authorRichard L. Bakst MD
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, NY, USA
Search for more papers by this authorVishal Gupta MD
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, NY, USA
Search for more papers by this authorKrzysztof J. Misiukiewicz MD
Department of Medical Oncology, Icahn School of Medicine at Mount Sinai, NY, USA
Search for more papers by this authorElizabeth Y. Chiao MD, MPH
Department of Internal Medicine and Health Services Research, Baylor College of Medicine, Houston, TX, USA
Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center, Houston, TX, USA
Search for more papers by this authorMichael E. Scheurer PhD, MPH
Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine, Houston, TX, USA
Search for more papers by this authorSimon Laban MD
Head and Neck Cancer Center Ulm, Department of Oto-Rhino-Laryngology and Head and Neck Surgery, University Medical Center Ulm, Ulm, Baden-Württemberg, Germany
Search for more papers by this authorDavid Zhang MD, MPH, PhD
Department of Pathology, Icahn school of Medicine at Mount Sinai, NY, USA
Search for more papers by this authorFei Ye MD
Department of Pathology, Icahn school of Medicine at Mount Sinai, NY, USA
Search for more papers by this authorMiao Cui MD
Department of Pathology, Icahn school of Medicine at Mount Sinai, NY, USA
Search for more papers by this authorElizabeth G. Demicco MD
Department of Pathology, Icahn school of Medicine at Mount Sinai, NY, USA
Search for more papers by this authorMarshall R. Posner MD
Department of Medical Oncology, Icahn School of Medicine at Mount Sinai, NY, USA
Search for more papers by this authorCorresponding Author
Andrew G. Sikora MD, PhD
Department of Otolaryngology – Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA
Corresponding author: A. G. Sikora, Bobby R. Alford Department of Otolaryngology–Head and Neck Surgery, One Baylor Plaza, NA-102, Houston, TX 77030. E-mail: [email protected]Search for more papers by this authorConflict of Interest: A.G.S. receives unrestricted research funding from Advaxis, LLC, to support an investigator-initiated clinical trial of therapeutic vaccination for HPV-related oropharyngeal cancer. Other authors have declared no conflict of interest.
Abstract
Background
The majority of human papillomavirus (HPV)-related oropharyngeal carcinomas (OPCs) are associated with HPV genotype 16; however, OPC can be associated with other high-risk non-HPV16 genotypes.
Methods
This was a retrospective analysis of patients with high-risk non-HPV16 OPC treated at a single tertiary institution. Sociodemographic and clinical information was obtained by chart review. HPV genotype was determined by polymerase chain reaction (PCR). Baseline data and outcomes were compared between HPV16 and high-risk non-HPV16 groups.
Results
High-risk non-HPV16 genotypes accounted for 9% of HPV-related OPC. Of the 27 total high-risk non-HPV16 OPCs, HPV35 was most prevalent (48%). High-risk non-HPV16 OPC presented at a slightly higher age (p = .021) and higher clinical T classification (p = .008) compared to HPV16 OPC, but there was no significant survival difference.
Conclusion
Clinical characteristics of high-risk non-HPV16 OPC were largely consistent with those of HPV16 OPC. Additional multi-institutional studies will be required to demonstrate conclusively that the favorable prognosis of patients with HPV16 applies to all high-risk HPV types. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1330–1337, 2016
Supporting Information
Additional Supporting Information may be found in the online version of this article.
| Filename | Description |
|---|---|
| hed24442-sup-0001-suppinfof1.tiff21.7 MB | Supporting Information Figure 1 |
| hed24442-sup-0002-suppinfof2.tiff9.1 MB | Supporting Information Figure 2 |
| hed24442-sup-0003-suppinfof3.tiff9 MB | Supporting Information Figure 3 |
| hed24442-sup-0004-suppinfof4.tiff7.9 MB | Supporting Information Figure 4 |
| hed24442-sup-0005-suppinfof5.tiff10.3 MB | Supporting Information Figure 5 |
| hed24442-sup-0006-suppinfots1.docx87.2 KB | Supporting Information Table S1 |
| hed24442-sup-0007-suppinfots2.docx79.6 KB | Supporting Information Table S2 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1 Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–2917.
- 2 Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol 2014; 50: 380–386.
- 3 Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008; 26: 612–619.
- 4 Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709–720.
- 5 de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13: 607–615.
- 6 Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24–35.
- 7 Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 26: 3128–3137.
- 8 Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24: 5630–5636.
- 9 Woods R Sr, O'Regan EM, Kennedy S, Martin C, O'Leary JJ, Timon C. Role of human papillomavirus in oropharyngeal squamous cell carcinoma: a review. World J Clin Cases 2014; 2: 172–193.
- 10 St Guily JL, Jacquard AC, Prétet JL, et al. Human papillomavirus genotype distribution in oropharynx and oral cavity cancer in France – the EDiTH VI study. J Clin Virol 2011; 51: 100–104.
- 11 Vidal AC, Smith JS, Valea F, et al. HPV genotypes and cervical intraepithelial neoplasia in a multiethnic cohort in the southeastern USA. Cancer Causes Control 2014; 25: 1055–1062.
- 12 de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995; 76(Pt 4): 1057–1062.
- 13 Kann BH, Buckstein M, Carpenter TJ, et al. Radiographic extracapsular extension and treatment outcomes in locally advanced oropharyngeal carcinoma. Head Neck 2014; 36: 1689–1694.
- 14 Hernandez BY, Goodman MT, Lynch CF, et al. Human papillomavirus prevalence in invasive laryngeal cancer in the United States. PLoS One 2014; 9: e115931.
- 15 Lee LA, Huang CG, Tsao KC, et al. Increasing rates of low-risk human papillomavirus infections in patients with oral cavity squamous cell carcinoma: association with clinical outcomes. J Clin Virol 2013; 57: 331–337.
- 16 Gao G, Chernock RD, Gay HA, et al. A novel RT-PCR method for quantification of human papillomavirus transcripts in archived tissues and its application in oropharyngeal cancer prognosis. Int J Cancer 2013; 132: 882–890.
- 17 Nichols AC, Dhaliwal SS, Palma DA, et al. Does HPV type affect outcome in oropharyngeal cancer? J Otolaryngol Head Neck Surg 2013; 42: 9.
- 18 Hopenhayn C, Christian A, Christian WJ, et al. Prevalence of human papillomavirus types in invasive cervical cancers from 7 US cancer registries before vaccine introduction. J Low Genit Tract Dis 2014; 18: 182–189.
- 19 Westra WH. Detection of human papillomavirus (HPV) in clinical samples: evolving methods and strategies for the accurate determination of HPV status of head and neck carcinomas. Oral Oncol 2014; 50: 771–779.
- 20 Posner MR, Lorch JH, Goloubeva O, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 2011; 22: 1071–1077.
- 21 Woo YL, Damay I, Stanley M, Crawford R, Sterling J. The use of HPV linear array assay for multiple HPV typing on archival frozen tissue and DNA specimens. J Virol Methods 2007; 142: 226–230.
- 22 Wei W, Shi Q, Guo F, et al. The distribution of human papillomavirus in tissues from patients with head and neck squamous cell carcinoma. Oncol Rep 2012; 28: 1750–1756.
- 23 Thibaudeau E, Fortin B, Coutlée F, et al. HPV prevalence and prognostic value in a prospective cohort of 255 patients with locally advanced HNSCC: a single-centre experience. Int J Otolaryngol 2013; 2013: 437815.
- 24 Levovitz C, Chen D, Ivansson E, et al. TGFβ receptor 1: an immune susceptibility gene in HPV-associated cancer. Cancer Res 2014; 74: 6833–6844.
- 25 Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years. Hum Vaccin 2011; 7: 1359–1373.
- 26 Scherpenisse M, Schepp RM, Mollers M, Meijer CJ, Berbers GA, van der Klis FR. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses. PLoS One 2013; 8: e74797.
- 27 Kosalaraksa P, Mehlsen J, Vesikari T, et al. An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11–15 years of age. Pediatr Infect Dis J 2015; 34: 627–634.
- 28 Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372: 711–723.
Citing Literature
